Following the LaLux Ladies Cup Basketball Cup Final at Amicale Steesel-Basket Esch on 11 March 2017, the analysis of the basketball player Alexandra Williams' sample resulted in a positive result due to the presence of Triamcinolone.
This information had been released to the public in mid-May by the Luxembourg Anti-Doping Agency (ALAD), with a b-sample to be tested.
The specified substance is listed in Section S.9 Glucocorticoids, from the World Anti-Doping Agency (WADA) List of Prohibited Substances and Methods in competition.
The analysis of sample B confirmed the result of analysis A.
ALAD hs announced that this is an anti-doping rule violation under Article 2.1 (Presence of a Prohibited Substance, its Metabolites or Markers in an Athlete's Sample) of the ALAD Code. By letter dated 16 May 2017, the Commission contacted the Disciplinary Committee against Doping (CDD) to determine and decide on the alleged violation of the anti-doping rule committed by Alexandra Williams.
CDD imposed a sanction of a two-year suspension starting from 13 July 2017. The decision may be appealed to the Supreme Disciplinary Council against Doping, which must be done within fourteen days.